Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Non-Current Assets: 2016-2024

Historic Other Non-Current Assets for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $589,000.

  • UroGen Pharma's Other Non-Current Assets rose 1726.76% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 1726.76%. This contributed to the annual value of $589,000 for FY2024, which is 71.10% down from last year.
  • UroGen Pharma's Other Non-Current Assets amounted to $589,000 in FY2024, which was down 71.10% from $2.0 million recorded in FY2023.
  • Over the past 5 years, UroGen Pharma's Other Non-Current Assets peaked at $2.7 million during FY2022, and registered a low of $66,000 during FY2020.
  • In the last 3 years, UroGen Pharma's Other Non-Current Assets had a median value of $2.0 million in 2023 and averaged $1.8 million.
  • In the last 5 years, UroGen Pharma's Other Non-Current Assets slumped by 75.00% in 2020 and then spiked by 1,886.36% in 2021.
  • UroGen Pharma's Other Non-Current Assets (Yearly) stood at $66,000 in 2020, then skyrocketed by 1,886.36% to $1.3 million in 2021, then spiked by 109.00% to $2.7 million in 2022, then dropped by 25.62% to $2.0 million in 2023, then plummeted by 71.10% to $589,000 in 2024.